project id: TCGA-PRAD; case submitter id: TCGA-XK-AAK1; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.85; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.47; rna integrity number: 7.9; age at index: 62; days to birth: -22965; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1950; age at diagnosis: 22965; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 979.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 3; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 575; days to sample procurement: 0; initial weight: 10.0; sample id: 0ceb86c8-949c-4917-b57c-e55eb5119295; sample submitter id: TCGA-XK-AAK1-01A; portion id: 398d4f2b-7a24-46fc-847f-ec0b3de70b09; portion submitter id: TCGA-XK-AAK1-01A-11; slide id: 5354527b-905c-4f39-b469-3a64d0bc56a2; slide submitter id: TCGA-XK-AAK1-01Z-00-DX1; percent lymphocyte infiltration: 3.0; percent monocyte infiltration: 0.0; percent necrosis: 1.0; percent neutrophil infiltration: 0.0; percent normal cells: 2.0; percent stromal cells: 40.0; percent tumor cells: 57.0; percent tumor nuclei: 90.0; section location: TOP;